Piper Jaffray Remains Sidelined on Teva Pharma (TEVA) Following 1Q - PT to $58
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Adamis Pharmaceuticals Announces License Agreement with Allergan plc Subsidiary for Epinephrine Pre-Filled Syringe
May 10, 2016 6:45 AM EDTDUBLIN, Ireland and SAN DIEGO, May 10, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (Adamis) has entered into an exclusive licensing agreement with Allergan plcs wholly owned subsidiary, Watson Laboratories, Inc. (Watson), to commercialize Adamis Epinephrine Pre-filled Syringe (PFS) product candidate for the emergency treatment of anaphylaxis.
Under the terms of the agreement, Watson will obtain commercial rights for the U.S. in exchange for an upfront fee and potential regulatory and performance based milestone payments totaling up to $32.5 million. Additionally, Watson will pay double-digit royalties to Adamis based on... More
Teva to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
May 9, 2016 11:00 AM EDTJERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Bank of America Merrill Lynch 2016 Health Care Conference. Siggi Olafsson will present on Tuesday, May 10, 2016 at 8:40 AM PT.
ÂWhat:
   Teva Presentation at the Bank of America Merrill Lynch Healthcare Conference ÂWho:
Siggi Olafsson, President and CEO, Global Generic Medicines,Â
Teva Pharmaceutical Industries Ltd.
 ... MoreTeva Reports First Quarter 2016 Results
May 9, 2016 7:00 AM EDTJERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter ended March 31, 2016.
   Q1 2016  Revenues $4.81 billion Cash flow from Operations $1.38 billion Non-GAAP EPS $1.20 GAAP EPS $0.62... More